Abbott India Limited has announced key board changes as part of its corporate governance updates, with one director stepping down and a new appointment taking effect in early 2026.

Director Resignation

Mr. Ambati Venu (DIN: 07614849) has tendered his resignation as Director of the Company, effective close of business hours on December 31, 2025. The resignation is to pursue an external career opportunity, with no other material reasons cited for the departure.

New Director Appointment

The Board of Directors has approved the appointment of Mr. Vivek Mohan as Additional Non-Executive Director, effective January 1, 2026. This appointment was made upon recommendation of the Nomination and Remuneration Committee through a resolution passed on December 24, 2025.

Professional Background of New Appointee

Mr. Vivek Mohan brings extensive experience within Abbott, having been appointed as Abbott's Vice President, Established Pharmaceuticals, India with effect from January 1, 2026. He previously served as Abbott's Divisional Vice President, Corporate Global Marketing, where he led creative strategy and marketing efforts for Abbott's corporate brand and managed brand partnerships and sponsorships including Real Madrid and the Abbott World Marathon Majors.

Mohan joined Abbott in 1992 as part of product development for Abbott Diagnostics in Illinois. His diverse leadership experience spans multiple geographies and includes:

• Senior Director - Integrated Health for Established Pharmaceuticals in India
• Managing Director for EPD in Abbott India Limited
• General Manager for Abbott Indonesia
• Regional commercial roles in North Yorkshire, UK and the Saudi/Gulf region

Educational Qualifications

Mr. Mohan holds strong academic credentials with a Bachelor of Science in Microbiology from the University of Michigan (1992) and an M.B.A. in International Business and Marketing from the University of Illinois (1996).

Regulatory Compliance and Next Steps

The company has confirmed that Mr. Vivek Mohan is not debarred from holding the office of director by virtue of any order of SEBI or any other authority. Additionally, he is not related to any of the Directors, Key Managerial Personnel, or Senior Management of the Company.

The Board has approved a Postal Ballot Notice to seek shareholder approval for Mr. Mohan's appointment as Director. The notice will be sent to shareholders in due course and filed with the Stock Exchange as per regulatory requirements under SEBI regulations.

Abbott India Limited , a prominent player in the pharmaceutical industry, has recently announced significant changes in its senior management, particularly within its Human Resources department.

New Leadership in Human Resources

Abbott India has appointed Ms. Vinutha Mufti as the new Director of Business Human Resources, effective December 16, 2025. This appointment comes as Mr. Rajan Kalantre, the current Director of Business Human Resources, is set to transition to another Abbott affiliate.

Key Details of the Transition

Mr. Kalantre will continue in his current role until December 15, 2025, ensuring a smooth transition of responsibilities.

Ms. Vinutha Mufti's Profile

Ms. Mufti brings over two decades of diverse HR experience to her new role at Abbott India. Her career highlights include:

• Joined Abbott in 2015 as Senior Manager - BHR for Nutrition
• Progressively held senior roles across Pharmaceuticals and Nutrition businesses
• Appointed as Head - BHR for Abbott's Primary Care business in 2020
• Became Associate Director - BHR for Nutrition in 2022
• Most recently served as Director - BHR for the Specialty Care business in 2023

Prior to joining Abbott, Ms. Mufti spent a decade at IBM in HRBP and Talent Management roles. Her educational background includes a B.E. in Electronics and Telecommunication from PCCE-Goa and a PGDBM in Management from Goa Institute of Management.

Impact and Expectations

This leadership change is expected to bring fresh perspectives to Abbott India's HR strategies. Ms. Mufti's extensive experience within Abbott and her prior role at IBM position her well to drive key initiatives in managerial effectiveness, diversity, equity, and inclusion (DEI), and talent management.

Abbott India's decision to promote from within for this crucial role demonstrates the company's commitment to nurturing internal talent and ensuring continuity in its HR leadership.

As the pharmaceutical industry continues to evolve, strong HR leadership will be vital in attracting, retaining, and developing top talent. Ms. Mufti's appointment is likely to play a significant role in shaping Abbott India's human resource strategies in the coming years.